The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 24, 2025
Filed:
Aug. 02, 2022
Applicant:
Medicenna Therapeutics, Inc., Toronto, CA;
Inventors:
Fahar Merchant, Vancouver, CA;
Shafique Fidai, Vancouver, CA;
Assignee:
Medicenna Therapeutics Inc., Toronto, CA;
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/55 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/76 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); A61K 35/76 (2015.01);
U.S. Cl.
CPC ...
C07K 14/55 (2013.01); A61K 38/1709 (2013.01); A61K 38/2013 (2013.01); A61K 39/0011 (2013.01); A61K 39/39541 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/76 (2013.01); C07K 16/2818 (2013.01); C07K 16/283 (2013.01); C07K 16/2896 (2013.01); C07K 19/00 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); A61K 35/76 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/55533 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/24134 (2013.01); C12N 2710/24143 (2013.01);
Abstract
Human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor as compared to wild-type IL-2 for use in combination therapies with anti-PD-1 antibodies for the treatment of cancer. Also provided are pharmaceutical compositions that include such anti-PD-1 antibodies and the disclosed IL-2 muteins.